BCAB – bioatla, inc. (US:NASDAQ)

News

BioAtla, Inc. (NASDAQ: BCAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com